| Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer ER Plimack, RL Dunbrack, TA Brennan, MD Andrake, Y Zhou, ... European urology 68 (6), 959-967, 2015 | 455 | 2015 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 242 | 2018 |
| Immunotherapy of prostate cancer: facts and hopes M Bilusic, RA Madan, JL Gulley Clinical Cancer Research 23 (22), 6764-6770, 2017 | 225 | 2017 |
| Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors M Bilusic, CR Heery, JM Collins, RN Donahue, C Palena, RA Madan, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 193 | 2019 |
| First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors J Strauss, CR Heery, JW Kim, C Jochems, RN Donahue, AS Montgomery, ... Clinical Cancer Research 25 (1), 99-109, 2019 | 129 | 2019 |
| Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations ME Gatti-Mays, JM Redman, JM Collins, M Bilusic Human vaccines & immunotherapeutics 13 (11), 2561-2574, 2017 | 112 | 2017 |
| Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer CR Meeker, DM Geynisman, BL Egleston, MJ Hall, KY Mechanic, ... Journal of oncology practice 12 (7), e755-e764, 2016 | 110 | 2016 |
| Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma M Bilusic, CR Heery, PM Arlen, M Rauckhorst, D Apelian, KY Tsang, ... Cancer Immunology, Immunotherapy 63, 225-234, 2014 | 109 | 2014 |
| Nivolumab-associated acute glomerulonephritis: a case report and literature review K Jung, X Zeng, M Bilusic BMC nephrology 17, 1-6, 2016 | 108 | 2016 |
| Clinical evaluation of TRICOM vector therapeutic cancer vaccines RA Madan, M Bilusic, C Heery, J Schlom, JL Gulley Seminars in oncology 39 (3), 296-304, 2012 | 104 | 2012 |
| Cancer vaccines PJ DeMaria, M Bilusic Hematology/Oncology Clinics 33 (2), 199-214, 2019 | 103 | 2019 |
| Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies J Strauss, ME Gatti-Mays, BC Cho, A Hill, S Salas, E McClay, JM Redman, ... Journal for immunotherapy of cancer 8 (2), 2020 | 90 | 2020 |
| Mapping the genetic determinants of hypertension, metabolic diseases, and related phenotypes in the lyon hypertensive rat M Bilusic, A Bataillard, MR Tschannen, L Gao, NE Barreto, M Vincent, ... Hypertension 44 (5), 695-701, 2004 | 69 | 2004 |
| Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer HA Sater, JL Marté, RN Donahue, B Walter-Rodriguez, CR Heery, ... Journal for immunotherapy of cancer 8 (1), 2020 | 47 | 2020 |
| A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)‐based immunotherapy vaccine regimen in patients with advanced cancer ME Gatti‐Mays, JM Redman, RN Donahue, C Palena, RA Madan, ... The oncologist 25 (6), 479-e899, 2020 | 46 | 2020 |
| Efficacy and safety of autologous dendritic cell–based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the … NJ Vogelzang, TM Beer, W Gerritsen, S Oudard, P Wiechno, ... JAMA oncology 8 (4), 546-552, 2022 | 45 | 2022 |
| Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition … I Grenga, RN Donahue, ML Gargulak, LM Lepone, M Roselli, M Bilusic, ... Urologic Oncology: Seminars and Original Investigations 36 (3), 93. e1-93. e11, 2018 | 45 | 2018 |
| A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. F Karzai, RA Madan, H Owens, A Couvillon, A Hankin, M Williams, ... Journal of Clinical Oncology 36 (6_suppl), 163-163, 2018 | 41 | 2018 |
| Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines M Bilusic, JL Gulley Cancer Immunology, Immunotherapy 61, 109-117, 2012 | 39 | 2012 |
| Randomized, double‐blind, placebo‐controlled Phase II study of yeast‐brachyury vaccine (GI‐6301) in combination with standard‐of‐care radiotherapy in locally advanced … PJ DeMaria, M Bilusic, DM Park, CR Heery, RN Donahue, RA Madan, ... The Oncologist 26 (5), e847-e858, 2021 | 37 | 2021 |
James L. GulleyNational Cancer InstituteEmail verificata su mail.nih.gov
